Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 11 | 2024 | 272 | 2.600 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 1075 | 1.470 |
Why?
|
| Lung Neoplasms | 9 | 2023 | 2262 | 1.190 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 736 | 1.160 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 69 | 0.920 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 1075 | 0.870 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 21 | 0.860 |
Why?
|
| Oropharyngeal Neoplasms | 5 | 2022 | 118 | 0.850 |
Why?
|
| Tongue Neoplasms | 1 | 2022 | 50 | 0.830 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 15 | 0.790 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2021 | 54 | 0.770 |
Why?
|
| Pneumonia | 1 | 2022 | 179 | 0.760 |
Why?
|
| Mouth Neoplasms | 1 | 2022 | 194 | 0.720 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2018 | 15 | 0.660 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 384 | 0.640 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 1052 | 0.590 |
Why?
|
| Radiotherapy | 2 | 2018 | 328 | 0.560 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 541 | 0.550 |
Why?
|
| Carcinoma | 3 | 2024 | 436 | 0.520 |
Why?
|
| Papillomavirus Infections | 3 | 2022 | 239 | 0.500 |
Why?
|
| Chemoradiotherapy | 5 | 2022 | 301 | 0.500 |
Why?
|
| Postoperative Complications | 4 | 2019 | 2207 | 0.490 |
Why?
|
| Immunotherapy | 4 | 2022 | 629 | 0.470 |
Why?
|
| Esophagectomy | 1 | 2014 | 84 | 0.460 |
Why?
|
| Anastomosis, Surgical | 1 | 2014 | 267 | 0.440 |
Why?
|
| Brain Neoplasms | 4 | 2019 | 763 | 0.440 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 321 | 0.400 |
Why?
|
| Retrospective Studies | 14 | 2024 | 8477 | 0.380 |
Why?
|
| Humans | 33 | 2024 | 86617 | 0.360 |
Why?
|
| Radiation Injuries | 3 | 2020 | 155 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 2436 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1313 | 0.310 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2023 | 98 | 0.310 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 1685 | 0.290 |
Why?
|
| Prospective Studies | 4 | 2022 | 4212 | 0.290 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 3636 | 0.280 |
Why?
|
| Sarcoma | 2 | 2018 | 212 | 0.280 |
Why?
|
| Ipilimumab | 2 | 2022 | 58 | 0.270 |
Why?
|
| Aged | 16 | 2024 | 18402 | 0.270 |
Why?
|
| Middle Aged | 18 | 2024 | 25017 | 0.260 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2018 | 173 | 0.250 |
Why?
|
| Neoplasm Staging | 5 | 2023 | 1937 | 0.250 |
Why?
|
| Papillomaviridae | 2 | 2022 | 153 | 0.240 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2024 | 66 | 0.230 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 155 | 0.220 |
Why?
|
| Re-Irradiation | 1 | 2022 | 15 | 0.220 |
Why?
|
| Tongue | 1 | 2022 | 57 | 0.210 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 42 | 0.200 |
Why?
|
| Adult | 13 | 2024 | 25640 | 0.200 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 2887 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 104 | 0.200 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 6501 | 0.200 |
Why?
|
| Drug Monitoring | 1 | 2022 | 118 | 0.200 |
Why?
|
| DNA, Viral | 1 | 2022 | 265 | 0.200 |
Why?
|
| Lymph Nodes | 2 | 2022 | 530 | 0.190 |
Why?
|
| Female | 18 | 2024 | 44509 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 71 | 0.190 |
Why?
|
| Male | 16 | 2024 | 40958 | 0.190 |
Why?
|
| Prognosis | 5 | 2022 | 3675 | 0.180 |
Why?
|
| Tissue Expansion | 1 | 2019 | 19 | 0.180 |
Why?
|
| Breast Implantation | 1 | 2019 | 12 | 0.180 |
Why?
|
| Breast Implants | 1 | 2019 | 23 | 0.170 |
Why?
|
| Xerostomia | 1 | 2018 | 10 | 0.170 |
Why?
|
| Submandibular Gland | 1 | 2018 | 16 | 0.170 |
Why?
|
| Salvage Therapy | 1 | 2020 | 233 | 0.170 |
Why?
|
| Free Tissue Flaps | 1 | 2019 | 49 | 0.170 |
Why?
|
| Osteonecrosis | 1 | 2018 | 21 | 0.160 |
Why?
|
| Spinal Neoplasms | 1 | 2018 | 50 | 0.160 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 14 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 592 | 0.160 |
Why?
|
| Treatment Outcome | 6 | 2022 | 7990 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 223 | 0.150 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 36 | 0.150 |
Why?
|
| Neoplasms | 2 | 2022 | 2898 | 0.150 |
Why?
|
| Necrosis | 1 | 2017 | 204 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1464 | 0.140 |
Why?
|
| Brachytherapy | 1 | 2017 | 119 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 860 | 0.140 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 231 | 0.140 |
Why?
|
| Survival Rate | 4 | 2021 | 1860 | 0.130 |
Why?
|
| Esophagitis | 1 | 2015 | 42 | 0.130 |
Why?
|
| Esophageal Stenosis | 1 | 2015 | 26 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1376 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 426 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 1 | 2013 | 83 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 621 | 0.110 |
Why?
|
| Quality of Life | 1 | 2020 | 1583 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2024 | 2767 | 0.100 |
Why?
|
| Carboplatin | 2 | 2022 | 286 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2358 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2022 | 460 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1721 | 0.080 |
Why?
|
| Brain | 1 | 2017 | 2216 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2022 | 1056 | 0.070 |
Why?
|
| Radiotherapy Dosage | 2 | 2020 | 468 | 0.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2020 | 176 | 0.070 |
Why?
|
| Margins of Excision | 1 | 2024 | 39 | 0.060 |
Why?
|
| Young Adult | 3 | 2022 | 5974 | 0.060 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 133 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 133 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 270 | 0.050 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 147 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2022 | 556 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 751 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 285 | 0.040 |
Why?
|
| Cisplatin | 1 | 2022 | 612 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 418 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 92 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 159 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 839 | 0.040 |
Why?
|
| Adolescent | 2 | 2022 | 8979 | 0.040 |
Why?
|
| Mammaplasty | 1 | 2019 | 105 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 250 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2017 | 40 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 3045 | 0.040 |
Why?
|
| United States | 2 | 2022 | 6665 | 0.040 |
Why?
|
| Mastectomy | 1 | 2019 | 236 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 597 | 0.040 |
Why?
|
| Acute Disease | 1 | 2018 | 826 | 0.040 |
Why?
|
| Registries | 1 | 2020 | 702 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2017 | 303 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 291 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1196 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 335 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 971 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 858 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1538 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 395 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1531 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 685 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 596 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 1577 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 5209 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 5417 | 0.020 |
Why?
|